Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Gilead to present Darusentan data

Gilead to present Darusentan data

14th April 2009

Gilead has announced it will present research results of a compound that is being investigated for the treatment of resistant hypertension.

Professor Michael A Weber, from the Suny Downstate Medical College of Medicine, will discuss the data from a phase III clinical trial evaluating the business’ Darusentan.

Intended for use as an add-on oral therapy, it is a propanoic-acid class endothelin receptor antagonist that helps prevent blood vessels narrowing and prohibiting cell proliferation.

The paper, titled Fixed Doses of Darusentan Compared to Placebo in Treatment resistant Hypertension, will be reviewed during the 24th Annual Scientific Meeting and Exposition, which will be held between May 6th and 9th.

Last week, Gilead received a paragraph IV certification notice letter from the Food and Drug Administration (FDA) informing the company that Teva had submitted an application for authorisation to manufacture and market a generic version of Atripla.

The drug is currently sold through a joint venture between Gilead and Bristol-Myers Squibb.

If the former decides to file a lawsuit against Teva for alleged patent infringement, the FDA’s final decision could be delayed for up to 30 months.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.